First-line Treatment of MCapOX + Cetuximab Vs. MFOLFOX6 + Cetuximab for RAS/BRAF Wild-type, MSS, Unresectable Left-Sided MCRC: a Multicenter, Randomized, Controlled, Phase III Study

Clinical trial NCT06616259 · NOT_YET_RECRUITING

Trial details

NCT number

NCT06616259

Sponsor

Meng Qiu

Status

NOT_YET_RECRUITING

Phase

Phase 3

Study type

INTERVENTIONAL

Start date

2024-09-26

Primary completion

2028-09-30

Enrollment

452

View on ClinicalTrials.gov